Benzyl Amines for Selective Glucocorticoid Receptor Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory compounds have limited selectivity towards the glucocorticoid receptor (GR) compared to other steroid receptors, leading to undesirable metabolic actions.
Innovation Solution
Development of stereoisomers with specific structural features, such as certain substituents and ring systems, to enhance selectivity towards the glucocorticoid receptor while minimizing metabolic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds with phthalides, thiophthalides, benzoxazinones or phthalazinones are used as anti-inflammatory agents, then anti-inflammatory action is achieved, but selectivity towards glucocorticoid receptor is insufficient leading to undesirable metabolic actions
Solution Approach 1:
The patent modifies the molecular structure of anti-inflammatory compounds by changing specific parameters - introducing a benzyl amine group (C6H5CH2NH2) at the C17 position of the glucocorticoid nucleus. This structural parameter change enhances the compound's selectivity for the glucocorticoid receptor while reducing binding to other steroid receptors, thereby minimizing metabolic side effects. The specific substitution pattern and stereochemistry (R or S configuration at C17) are optimized to achieve this selective binding.
Solution Approach 2:
The patent utilizes asymmetric substitution at the C17 position of the glucocorticoid nucleus, where a single benzyl amine group is introduced instead of symmetric or multiple substitutions. This asymmetric modification creates a specific three-dimensional arrangement that preferentially interacts with the glucocorticoid receptor binding site, enhancing selectivity. The chiral center at C17 (with R or S configuration) further contributes to this asymmetric recognition mechanism.
2Reliability
If existing anti-inflammatory compounds are used, then anti-inflammatory effect is obtained, but dissociation between anti-inflammatory action and metabolic actions occurs
Solution Approach 1:
The patent applies local quality modification by introducing the benzyl amine group specifically at the C17 position of the glucocorticoid nucleus, while maintaining the core anti-inflammatory pharmacophore (C21 ketone and C11 hydroxyl group). This localized structural change at C17 enhances receptor selectivity without compromising the essential anti-inflammatory activities mediated by the core structure, thereby separating the beneficial anti-inflammatory effect from harmful metabolic actions.
Data Source
AI summary
The present invention relates to the compounds of formula (I), processes for their production and their use as anti-inflammatory agents.